Summary: Duloxetine is a balanced selective serotonin and norepinephrine-reuptake inhibitor available in the United States for the treatment of major depressive disorder (MDD) and diabetic ...

Tatton MP Esther McVey has called on the government to provide better guidance to people who are coming off anti-depressants ...

017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with narcolepsy. AXS-12 is an investigational highly selective potent norepinephrine reuptake ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

Singer Neha Bhasin shares her battle with PMDD a severe condition beyond PMS Learn about symptoms treatments and the ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...

Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III ...

CBT is a structured, goal-oriented psychotherapy that focuses on the relationship between a person's thoughts, feelings, and ...

In patients receiving serotonergic medications in combination with an MAOI, there have been reports of serious and sometimes fatal reactions, including hyperthermia, rigidity, myoclonus, autonomic ...